查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018592

即時血糖監測市場：依產品類型、測試類型、技術、可攜性、最終用戶和通路分類－2026-2032年全球市場預測

Point-of-Care Glucose Testing Market by Product Type, Test Type, Technology, Portability, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，即時血糖監測市場價值將達到 76.5 億美元，到 2026 年將成長至 81.4 億美元，到 2032 年將達到 131 億美元，複合年成長率為 7.98%。

主要市場統計數據
基準年 2025 76.5億美元
預計年份：2026年 81.4億美元
預測年份 2032 131億美元
複合年成長率 (%) 7.98%

從權威的角度闡述了技術整合、數位系統和以患者為中心的醫療保健服務如何改變即時血糖監測和護理路徑。

即時血糖監測在現代糖尿病診療流程中發揮核心作用，其速度、準確性和便利性直接影響臨床療效和患者的生活品質。過去十年，臨床實踐和消費者期望推動了診斷方式的轉變，從間歇性的檢查室轉向持續的、面對面的監測，從而支持即時治療決策和遠距醫療模式。這項轉變得益於許多領域的進步，包括提高訊號保真度的感測器化學和光電、實現連續資料流的小型化電子元件和連接技術，以及將血糖值資料流轉化為臨床應用價值的互通軟體應用程式。

即時監測、混合分銷模式、感測器創新和整合軟體平台如何改變血糖監測領域的競爭格局和臨床動態。

床邊血糖監測領域正經歷變革性的轉變，重塑著競爭格局、臨床工作流程和病患期望。即時、連續血糖監測已從小眾工具發展成為主流臨床實踐，實現了預防性血糖控制和遠端患者管理。這促使人們加大對感測器多樣化的投資。雖然酵素感測器仍然是許多應用的基礎，但新興的光學方法旨在降低侵入性並提高使用者舒適度。同時，軟體應用也從被動記錄工具發展成為整合平台，能夠提供決策支援、遠端傳輸資料給醫療團隊，以及透過演算法驅動的警報來緩解急性事件。

2025 年美國貿易政策調整對血糖檢測領域的採購、製造地、分銷經濟和戰略供應商風險管理的影響。

美國於2025年實施的關稅和貿易政策調整對照護現場血糖監測設備及耗材的製造選擇、籌資策略以及全球供應鏈設計產生了直接且連鎖的影響。半導體晶片、特殊光學元件和化學試劑等組件可能需要經過多條國際供應鏈，而關稅波動改變了供應商的相對經濟效益，促使企業重新評估契約製造、本地化生產和庫存策略。因此，採購團隊正在重新調整供應商選擇標準，除了傳統的品質和成本指標外，還將貿易風險和物流韌性納入考量。

策略性細分分析揭示了產品架構、最終用戶工作流程、通路、測量方法和可移植性選項如何影響部署和設計優先順序。

基於細分市場的分析觀點了產品、終端用戶、分銷管道、測試類型、技術和便攜性等方面的潛在機會和營運挑戰。就產品類型而言，涵蓋間歇掃描和即時監測方法的連續血糖監測設備正在重新定義監測頻率和臨床醫生工作流程，而傳統的血糖儀和試紙對於即時檢測以及不適合連續監測的環境仍然至關重要。在感測器領域，成熟的酶法和旨在降低侵入性並提高用戶接受度的新型光學感測器之間正在形成兩極化。此外，軟體應用程式作為整合層，在將原始資料轉化為可管理流程方面發揮越來越重要的作用。

美洲、歐洲、中東和非洲以及亞太地區的區域管理體制、支付方趨勢、製造地和通路偏好如何決定產品的採用路徑？

區域趨勢在整個照護現場和地方支付方的監管流程和報銷機制各不相同，因此需要製定個人化的、基於實證醫學的定價策略，以滿足公共和私人購買方的需求。

差異化的產品系列、整合的數位生態系統、通路策略和供應鏈韌性如何塑造領先的血糖監測公司的競爭優勢。

主要企業之間的競爭格局日益受到產品組合廣度、數位生態系統整合以及在不同醫療環境中提供臨床療效的能力的影響。領先的醫療設備製造商致力於拓展連續血糖監測功能，同時保持其在血糖儀和試紙領域的領先地位，以應對各種臨床情境。與軟體開發商和遠端醫療服務提供者建立策略合作夥伴關係，使供應商能夠提供護理管理服務，從而提高治療依從性、支持遠端劑量調整併產生真實世界數據，為醫保報銷提供更有力的依據。

為醫療設備製造商和銷售團隊提供可操作的策略重點，以加速產品部署、分散風險，並使產品創新與保險公司和臨床需求保持一致。

產業領導企業應採取多管齊下的策略，優先考慮技術多元化、通路創新和業務永續營運，以實現成長並降低風險。首先，他們應有選擇地投資於感測器技術的進步，以降低侵入性並改善用戶體驗，同時保持分析的穩健性；並同時開發模組化架構，以便快速整合新的感測器化學和光學元件。其次，他們應透過建立可互通的軟體平台來擴展其數位化能力，這些平台可提供臨床醫生決策支援、病人參與工具和用藥依從性計劃，從而創造永續的收入來源，以抵消硬體利潤率面臨的壓力。

檢驗可操作的見解，該框架結合了相關人員訪談、監管和專利分析、臨床文獻綜述和供應鏈情境檢驗。

本報告的分析整合了初步的定性研究結果和全面的二手證據，旨在深入理解臨床、商業性和技術趨勢。初步研究包括對臨床醫生、採購經理、診斷檢查室管理人員、居家照護提供者、連鎖藥局負責人和製造企業高管進行結構化訪談，以收集他們對設備性能、工作流程整合和分銷偏好的第一手觀點。這些研究結果與監管申報文件、同行評審的臨床研究、設備核准摘要、專利趨勢回顧和技術可行性評估進行了交叉比對，以檢驗技術主張和應用促進因素。

簡要概述技術進步、不斷變化的分銷管道和供應鏈韌性如何共同為糖尿病護理領域的相關人員帶來策略挑戰。

即時血糖監測正處於一個轉折點，技術創新、不斷演進的醫療服務模式和不斷變化的商業性格局在此交匯，既帶來了機遇，也帶來了挑戰。連續監測技術、感測器化學和光學技術的進步，以及更完善的軟體生態系統，正推動著從間歇性監測向持續性、一體化護理管理的轉變。同時，涵蓋直銷、醫院、零售藥局和線上市場的不斷演變的分銷管道，以及關稅調整等政策趨勢，都要求商業領導者在採購、定價和通路策略中融入敏捷性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 即時血糖監測市場：依產品類型分類

  • 連續血糖監測設備
    • 間歇掃描
    • 即時的
  • 血糖儀
  • 感應器
    • 酵素配方
    • 光學的
  • 軟體應用
  • 測試條

第9章 依檢測類型分類的即時血糖監測市場

  • 侵入性
  • 微創
  • 非侵入性

第10章：即時血糖監測市場：依技術分類

  • 比色法
  • 電化學公式
  • 光強度

第11章 即時血糖監測市場：攜帶式

  • 固定式
  • 可攜式的

第12章 即時血糖監測市場：依最終用戶分類

  • 門診手術中心
  • 診斷檢查室
    • 醫院檢查室
    • 獨立檢測實驗室
  • 居家照護
    • 居家照護
    • 自我測量
  • 醫院和診所
    • 大型醫院
    • 小規模診所

第13章：即時血糖監測市場：依通路分類

  • 直銷
  • 醫院藥房
  • 網路藥房
    • 製造商網站
    • 第三方市場
  • 零售藥房

第14章 即時血糖監測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 即時血糖監測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 即時血糖監測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國即時血糖監測市場

第18章：中國即時血糖監測市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AgaMatrix, Inc.
  • Ascensia Diabetes Care Holdings AG
  • B. Braun Melsungen AG
  • Bayer AG
  • Becton, Dickinson and Company
  • Dexcom, Inc.
  • EKF Diagnostics Holdings plc
  • F. Hoffmann-La Roche Ltd
  • GlySens, Inc.
  • HemoCue AB（Radiometer Group）
  • i-Health Labs, Inc.
  • i-SENS, Inc.
  • Johnson & Johnson
  • Medtronic plc
  • Nipro Corporation
  • Nova Biomedical Corporation
  • Sinocare Inc.
  • Trividia Health, Inc.
Product Code: MRR-B9334AD6C44F

The Point-of-Care Glucose Testing Market was valued at USD 7.65 billion in 2025 and is projected to grow to USD 8.14 billion in 2026, with a CAGR of 7.98%, reaching USD 13.10 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.65 billion
Estimated Year [2026] USD 8.14 billion
Forecast Year [2032] USD 13.10 billion
CAGR (%) 7.98%

An authoritative orientation to how converging technologies, digital systems, and patient-centric delivery are reshaping point-of-care glucose testing and care pathways

Point-of-care glucose testing occupies a central role in contemporary diabetes care pathways, where speed, accuracy, and accessibility determine clinical outcomes and patient quality of life. Over the past decade clinical practice and consumer expectations have pushed diagnostics from episodic laboratory tests toward continuous, near-patient monitoring that supports real-time therapeutic decisions and remote care models. This evolution has been driven by advances across multiple domains: sensor chemistry and photonics that improve signal fidelity, miniaturized electronics and connectivity that enable persistent data flows, and interoperable software applications that translate streams of glucose readings into clinically actionable insights.

Consequently, stakeholders across the ecosystem are recalibrating priorities. Device manufacturers are balancing investments between traditional glucose meters and test strips, while expanding portfolios to include continuous glucose monitoring devices and complementary sensors. Health systems and payers are evaluating the clinical and operational trade-offs of ambulatory surgical centers versus hospital-based laboratories, and the rise of assisted and self-monitoring paradigms at home is reshaping distribution choices. In parallel, a growing emphasis on non-invasive and minimally invasive test types, coupled with distinct technology approaches such as colorimetric, electrochemical, and photometric methods, is broadening the pathways through which innovation can reach clinicians and consumers.

As a result, point-of-care glucose testing is no longer solely a laboratory concern but a strategic domain that intersects with digital health, retail distribution, and care delivery redesign. This report synthesizes those intersections so clinical leaders, R&D teams, and commercial strategists can navigate the complex landscape with clarity and make decisions that align product development, channel strategy, and regulatory engagement for maximal clinical and economic impact.

How real-time monitoring, hybrid distribution models, sensor innovation, and integrated software platforms are collectively transforming competitive and clinical dynamics in glucose testing

The landscape of point-of-care glucose testing is undergoing transformative shifts that are redefining competitive boundaries, clinical workflows, and patient expectations. Real-time continuous glucose monitoring has moved from a specialized tool into mainstream clinical practice, enabling proactive glycemic control and remote patient management. This has catalyzed investment in sensor diversity, where enzymatic sensors remain foundational for many applications while emerging optical approaches aim to reduce invasiveness and improve user comfort. At the same time, software applications have matured from passive logging tools into integrated platforms that enable decision support, telemetry to care teams, and algorithm-driven alerts that reduce acute events.

Concurrently, distribution dynamics are shifting toward hybrid models that blend direct sales, hospital and retail pharmacy networks, and increasingly sophisticated online pharmacy channels that include manufacturer storefronts and third-party marketplaces. The rise of home-based monitoring, both self-managed and assisted, is prompting manufacturers to prioritize portability and user-centric design, while benchtop platforms continue to serve diagnostic laboratories and large hospital installations. Diagnostic laboratories themselves are segmented into hospital-based and independent facilities, creating differentiated procurement cycles and clinical integration challenges. These shifts are compounded by regulatory and reimbursement changes that are encouraging cross-sector partnerships between device companies, health systems, and digital health vendors.

Taken together, these transformative movements demand a strategic response that combines product differentiation, distribution innovation, and clinical evidence generation. Industry participants who align sensor technology choices-whether electrochemical, photometric, or colorimetric-with targeted end-user workflows, and who build interoperable software layers to support clinician and patient decision-making, will be better positioned to capture clinical adoption and scale sustainably.

Implications of 2025 United States trade policy adjustments on sourcing, manufacturing footprints, distribution economics, and strategic supplier risk management in glucose testing

The introduction of tariffs and trade policy adjustments in the United States during 2025 has had immediate and cascading implications across manufacturing choices, procurement strategies, and global supply chain design for devices and consumables used in point-of-care glucose testing. Components such as semiconductor chips, specialized optics, and chemical reagents can traverse multiple international supply chains, and tariff shifts alter the relative economics of sourcing locations, incentivizing companies to reassess contract manufacturing, localization of production, and inventory strategies. Consequently, procurement teams have reprioritized supplier qualification criteria to include trade exposure and logistics resilience alongside traditional quality and cost metrics.

In practical terms, companies have responded by diversifying supplier bases and exploring regional manufacturing footprints that can mitigate tariff exposure while preserving access to critical components. For products with thinner margins, such as test strips, tariff-driven cost pressure is particularly acute and has accelerated negotiations with distribution partners to re-evaluate pricing frameworks and payment terms. Software-centric offerings and cloud-based services have experienced a different dynamic; with lower physical component dependence, these solutions have become strategic differentiators that can offset hardware cost pressures by delivering added value through analytics, adherence programs, and remote monitoring services.

Moreover, the policy environment has nudged industry participants to improve transparency in their supply chains and to engage more proactively with payers and procurement bodies to align reimbursement pathways with evolving cost structures. While tariffs alone do not determine long-term competitive outcomes, they have sharpened focus on operational agility, supplier risk management, and strategic partnerships, and they have accelerated a shift toward business models that emphasize recurring revenue through software and service offerings as a hedge against hardware-related cost volatility.

Strategic segmentation analysis revealing how product architectures, end-user workflows, distribution pathways, assay modalities, and portability choices shape adoption and design priorities

A segmentation-driven lens reveals nuanced opportunities and operational challenges across product, end user, distribution, test type, technology, and portability dimensions. In product type, continuous glucose monitoring devices, which encompass both intermittently scanned and real-time systems, are redefining expectations around monitoring frequency and clinician workflows, while traditional glucose meters and test strips remain vital for point checks and settings where continuous monitoring is less practical. Sensors present a bifurcation between enzymatic approaches with well-established analytical performance and newer optical sensors that aim to achieve lower invasiveness and improved user acceptance; software applications increasingly serve as the integrative layer that translates raw readings into management pathways.

With respect to end users, ambulatory surgical centers demand rapid, reliable point-of-care results integrated into perioperative decision-making, whereas diagnostic laboratories-both hospital-based and independent-require standardized workflows and connectivity for lab information systems. Home care has bifurcated into assisted home care and self-monitoring populations, each with distinct usability and support needs, and hospitals and clinics, spanning large hospital systems to small clinics, have contrasting procurement cycles and clinical integration requirements. Distribution channels vary from direct sales models that support clinical account management to hospital pharmacies and retail pharmacies that prioritize supply continuity, while online pharmacies, whether manufacturer-operated storefronts or third-party marketplaces, are increasingly important for direct-to-consumer access.

Test types, categorized into invasive, minimally invasive, and non-invasive methodologies, create specific regulatory and clinical evidence demands that shape development timelines and adoption curves. Technology choices-colorimetric, electrochemical, and photometric-bring different performance, cost, and manufacturability trade-offs that must be matched to intended use cases. Portability considerations, whether benchtop or portable, further influence product design and target audiences. In synthesis, the most successful product strategies will be those that align sensor chemistry and assay format with targeted end-user workflows and distribution pathways, supported by software features that reduce friction and enhance clinical utility.

How regional regulatory regimes, payer dynamics, manufacturing footprints, and channel preferences across the Americas, Europe Middle East & Africa, and Asia-Pacific determine adoption pathways

Regional dynamics play a decisive role in shaping clinical adoption, regulatory strategies, and supply chain choices across the point-of-care glucose testing ecosystem. In the Americas, care delivery is characterized by a strong emphasis on outpatient and home-based monitoring, rapid adoption of continuous glucose monitoring technologies, and a commercial environment where payer negotiation and value demonstration are critical for scale. Regulatory processes and reimbursement mechanisms vary between national and subnational payers, necessitating tailored evidence generation and pricing strategies that resonate with both public and private purchasers.

Within Europe, Middle East & Africa, regulatory harmonization efforts and diversified healthcare infrastructure create both opportunities and complexity. Western European markets often exhibit high standards for clinical evidence and interoperability, while parts of the Middle East and Africa emphasize affordability and supply chain robustness, encouraging partnerships that localize assembly or distribution. In contrast, Asia-Pacific is highly heterogeneous with pockets of rapid technological uptake, substantial domestic manufacturing capacity, and varying regulatory regimes; in some economies, local manufacturers are significant players and procurement is influenced by national industrial policies. Across all regions, online pharmacy penetration, direct-to-consumer channels, and retail pharmacy networks influence how devices and consumables reach patients, and regional differences in clinical practice guidelines shape the prioritization of continuous versus episodic monitoring.

Therefore, companies seeking international expansion must design regulatory, commercial, and supply chain strategies that reflect regional idiosyncrasies. This requires investing in localized evidence generation, building distribution relationships that align with hospital and pharmacy procurement models, and, where appropriate, establishing regional manufacturing or assembly capabilities to reduce lead times and mitigate tariff exposure.

How differentiated portfolios, digital ecosystem integration, channel strategies, and supply chain resilience are shaping competitive advantage among leading glucose testing companies

Competitive dynamics among leading companies are increasingly shaped by portfolio breadth, integration of digital ecosystems, and the ability to deliver clinical outcomes across diverse care settings. Market-leading device manufacturers have focused on extending continuous glucose monitoring capabilities while maintaining presence in glucose meters and test strip segments to serve a wide range of clinical scenarios. Strategic partnerships with software developers and telehealth providers have enabled device vendors to offer care management services that improve adherence, support remote titration of therapies, and generate real-world evidence that strengthens reimbursement cases.

At the same time, smaller and niche players are targeting differentiated sensor technologies, including optical and novel minimally invasive approaches, to capture specialist use cases and to create acquisition targets for larger firms seeking technological acceleration. Distribution strategies vary; some companies emphasize direct sales and hospital pharmacy relationships to secure institutional adoption, while others pursue omnichannel commercialization that leverages retail pharmacy networks and online marketplaces for consumer reach. Supply chain resilience, including dual sourcing and regional manufacturing, has become a strategic priority, and companies that combine robust quality systems with flexible manufacturing arrangements are better positioned to manage component volatility. Overall, firms that can integrate hardware, software, services, and channel execution into a coherent proposition will have an advantage in convincing clinicians, payers, and patients of the sustained value of their offerings.

Actionable strategic priorities for device makers and commercial teams to accelerate adoption, diversify risk, and align product innovation with payer and clinical needs

Industry leaders should adopt a multi-dimensional strategy that prioritizes technological diversification, channel innovation, and operational resilience to capture growth and mitigate risk. First, invest selectively in advancing sensor technologies that reduce invasiveness and improve user experience while preserving analytical robustness, and concurrently develop modular architectures that allow rapid integration of new sensor chemistries or optical components. Second, expand digital capabilities by building interoperable software platforms that deliver clinician decision support, patient engagement tools, and adherence programs, thereby creating recurring revenue streams that offset hardware margin pressures.

Additionally, diversify manufacturing and supplier footprints to reduce exposure to trade-policy shocks and logistics disruptions, and consider regional manufacturing or assembly to shorten lead times for critical consumables. Strengthen partnerships with hospitals, diagnostic laboratories-both hospital-based and independent-and pharmacy networks, including manufacturer-operated online channels and third-party marketplaces, to create a balanced distribution mix that reaches patients across ambulatory surgical centers, home care settings, and clinics of varying sizes. Finally, engage early with regulators and payers to design evidence-generation programs that demonstrate clinical utility and cost-effectiveness across invasive, minimally invasive, and non-invasive test modalities, and incorporate scenario planning into commercial forecasts to ensure agility in the face of policy or reimbursement shifts.

A rigorous mixed-methods research framework combining stakeholder interviews, regulatory and patent analysis, clinical literature review, and supply chain scenario testing to validate actionable insights

The analysis underpinning this report synthesizes primary qualitative insights with comprehensive secondary evidence to build a robust understanding of clinical, commercial, and technological dynamics. Primary research included structured interviews with clinicians, procurement leaders, diagnostic laboratory managers, home care providers, pharmacy chain strategists, and manufacturing executives to capture frontline perspectives on device performance, workflow integration, and distribution preferences. These insights were triangulated with regulatory filings, peer-reviewed clinical studies, device approval summaries, patent landscape reviews, and technology feasibility assessments to validate technical claims and adoption drivers.

Methodologically, the study applies a segmentation framework across product types, end users, distribution channels, test types, technologies, and portability to ensure findings are actionable for discrete commercial strategies. Supply chain and tariff sensitivity analyses were conducted using supplier mapping and scenario-based impact assessments to highlight operational vulnerabilities and mitigation options. Finally, the research was subjected to internal validation workshops with domain experts to prioritize strategic implications and to ensure the recommendations are aligned with clinical practice realities and commercial operational constraints.

A concise synthesis of how technological advances, distribution evolution, and supply chain resilience combine to create strategic imperatives for diabetes care stakeholders

Point-of-care glucose testing is at an inflection point where technological innovation, evolving care delivery models, and shifting commercial dynamics converge to create both opportunity and complexity. Continuous monitoring technologies, advances in sensor chemistry and optics, and more capable software ecosystems are enabling a shift from episodic measurement to continuous, integrated care management. At the same time, distribution evolution-spanning direct sales, hospital and retail pharmacies, and online marketplaces-and policy dynamics such as tariff adjustments require commercial leaders to build agility into their sourcing, pricing, and channel strategies.

Ultimately, success in this environment will favor organizations that can align product design with targeted end-user workflows, leverage software and services to amplify clinical value, and construct resilient supply chains that mitigate trade and logistics risk. By combining precise segmentation, regionally informed strategies, and disciplined evidence generation, stakeholders can convert the current period of change into a sustained competitive advantage and improved outcomes for patients living with diabetes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Point-of-Care Glucose Testing Market, by Product Type

  • 8.1. Continuous Glucose Monitoring Devices
    • 8.1.1. Intermittently Scanned
    • 8.1.2. Real Time
  • 8.2. Glucose Meters
  • 8.3. Sensors
    • 8.3.1. Enzymatic
    • 8.3.2. Optical
  • 8.4. Software Apps
  • 8.5. Test Strips

9. Point-of-Care Glucose Testing Market, by Test Type

  • 9.1. Invasive
  • 9.2. Minimally Invasive
  • 9.3. Non Invasive

10. Point-of-Care Glucose Testing Market, by Technology

  • 10.1. Colorimetric
  • 10.2. Electrochemical
  • 10.3. Photometric

11. Point-of-Care Glucose Testing Market, by Portability

  • 11.1. Benchtop
  • 11.2. Portable

12. Point-of-Care Glucose Testing Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Diagnostic Laboratories
    • 12.2.1. Hospital Based Labs
    • 12.2.2. Independent Labs
  • 12.3. Home Care
    • 12.3.1. Assisted Home Care
    • 12.3.2. Self Monitoring
  • 12.4. Hospitals & Clinics
    • 12.4.1. Large Hospitals
    • 12.4.2. Small Clinics

13. Point-of-Care Glucose Testing Market, by Distribution Channel

  • 13.1. Direct Sales
  • 13.2. Hospital Pharmacies
  • 13.3. Online Pharmacies
    • 13.3.1. Manufacturer Websites
    • 13.3.2. Third Party Marketplaces
  • 13.4. Retail Pharmacies

14. Point-of-Care Glucose Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Point-of-Care Glucose Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Point-of-Care Glucose Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Point-of-Care Glucose Testing Market

18. China Point-of-Care Glucose Testing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. AgaMatrix, Inc.
  • 19.7. Ascensia Diabetes Care Holdings AG
  • 19.8. B. Braun Melsungen AG
  • 19.9. Bayer AG
  • 19.10. Becton, Dickinson and Company
  • 19.11. Dexcom, Inc.
  • 19.12. EKF Diagnostics Holdings plc
  • 19.13. F. Hoffmann-La Roche Ltd
  • 19.14. GlySens, Inc.
  • 19.15. HemoCue AB (Radiometer Group)
  • 19.16. i-Health Labs, Inc.
  • 19.17. i-SENS, Inc.
  • 19.18. Johnson & Johnson
  • 19.19. Medtronic plc
  • 19.20. Nipro Corporation
  • 19.21. Nova Biomedical Corporation
  • 19.22. Sinocare Inc.
  • 19.23. Trividia Health, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INTERMITTENTLY SCANNED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INTERMITTENTLY SCANNED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INTERMITTENTLY SCANNED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY REAL TIME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY REAL TIME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY REAL TIME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY GLUCOSE METERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY GLUCOSE METERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY GLUCOSE METERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ENZYMATIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ENZYMATIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ENZYMATIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY OPTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY OPTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY OPTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SOFTWARE APPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SOFTWARE APPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SOFTWARE APPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST STRIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST STRIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY NON INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY NON INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY NON INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COLORIMETRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ELECTROCHEMICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ELECTROCHEMICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ELECTROCHEMICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PHOTOMETRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PHOTOMETRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PHOTOMETRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY BENCHTOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY BENCHTOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY BENCHTOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITAL BASED LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITAL BASED LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITAL BASED LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ASSISTED HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ASSISTED HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ASSISTED HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SELF MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SELF MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SELF MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY LARGE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY LARGE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY LARGE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SMALL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SMALL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SMALL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY THIRD PARTY MARKETPLACES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY THIRD PARTY MARKETPLACES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY THIRD PARTY MARKETPLACES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 232. GCC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. GCC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. GCC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 235. GCC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 236. GCC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. GCC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. GCC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. GCC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 241. GCC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 242. GCC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 243. GCC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. GCC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 271. G7 POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 272. G7 POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. G7 POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 274. G7 POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 275. G7 POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. G7 POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. G7 POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 278. G7 POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. G7 POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 280. G7 POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 281. G7 POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 282. G7 POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 283. G7 POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 284. NATO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 285. NATO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. NATO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 287. NATO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2032 (USD MILLION)
  • TABLE 288. NATO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. NATO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. NATO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 291. NATO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. NATO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 293. NATO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 294. NATO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 295. NATO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 296. NATO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 297. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)

TABL